KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Impact of solriamfetol treatment on sleep quality in Chinese patients with OSA-EDS: results of a randomized controlled trial. PMID 41788715 · Front Med (Lausanne) · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison. PMID 41788456 · Biologics · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial. PMID 41779821 · PLoS One · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intramuscular Generic Injection (QLG2072) versus Haloperidol in Chinese Patients with Acute Agitation: A Phase 3 Multicenter, Randomized, Double-Blind, Active-Controlled Trial. PMID 41778148 · Drug Des Devel Ther · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Partially covered or uncovered metal stent efficacy in malignant unresectable distal biliary obstruction (METARSI): Randomized multicenter trial. PMID 41777335 · Endosc Int Open · 2026 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Quality of Recovery After Laparoscopic Ovarian Cystectomy: A Randomized Controlled Trial Comparing Opioid-Free Multimodal Analgesia Versus Opioid-Based Anesthesia. PMID 41773363 · Clin Ter · 2026 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Hybrid Machine Learning Method and Standard Data Analysis Approaches for Predicting Treatment Outcomes of Cardiovascular Diseases: A Randomized Controlled Trial. PMID 41773358 · Clin Ter · 2026 The study is not in oncology and does not involve a drug intervention, which are mandatory criteria for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intertransverse Process Block versus Erector Spinae Plane Block as Adjuncts to an Interpectoral Block for Breast Cancer Surgery: A Randomized Controlled Trial. PMID 41768106 · J Pain Res · 2026 The trial is a randomized, oncology (breast cancer) study but evaluates anesthetic techniques, not a drug intervention for efficacy. The primary endpoint is morphine consumption (a safety/efficacy measure), not a time-to-event endpoint like OS or PFS. Therefore, it does not meet the core eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effectiveness of the AI-based RehabLung mobile rehabilitation system on cardiopulmonary function and user satisfaction in lung cancer patients undergoing thoracic surgery: a protocol for a two-arm randomized clinical trial. PMID 41762649 · Ther Adv Respir Dis · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Reversal of Pharmacologic Mydriasis in Pediatric Subjects with Ryzumvi (0.75% Phentolamine Ophthalmic Solution): A Post-Hoc Pooled Analysis from Three Randomized, Placebo-Controlled Phase 3 Trials. PMID 41743463 · Clin Ophthalmol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of soybean meal levels in grow-finisher pig diets for growth and nutrient metabolism. PMID 41743422 · Transl Anim Sci · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Validation of the Zürich composite measure pain scale (ZCMPS) for abdominal pain assessment in cows. PMID 41740193 · Vet Anaesth Analg · 2026 仅见动物/临床前证据,不是人体临床试验。
H
仅历史库存 excludednon_human pending 0 Figure · 0 Panel · risk -
Assessment of the Effectiveness, Tolerability, and Safety of the Preservative-Free Fixed Combination of Timolol, Dorzolamide, and Brimonidine Compared to Separate Therapies in Patients with Glaucoma, a Randomized Controlled Trial. PMID 41737851 · Clin Ophthalmol · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A short-term, exploratory randomized controlled trial on the safety and feasibility of intraoperative raltitrexed peritoneal chemotherapy in laparoscopic radical resection for advanced colorectal cancer. PMID 41737519 · Front Surg · 2026 The study is an exploratory randomized trial in oncology with a drug intervention, but it is not a Phase III or definitive trial, and its primary endpoints are safety/feasibility, not a time-to-event efficacy endpoint required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer. PMID 41737486 · Front Oncol · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass). PMID 41732658 · Ther Adv Med Oncol · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Flavored Vitamin-Mineral Supplementation via Water Improves the Performance of Newly Weaned Piglets. PMID 41721600 · Anim Sci J · 2026 仅见动物/临床前证据,不是人体临床试验。
H
仅历史库存 excludednon_human pending 0 Figure · 0 Panel · risk -
Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials. PMID 41712432 · Expert Opin Biol Ther · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies. PMID 41710044 · Rheumatol Adv Pract · 2026 The study is a randomized Phase 3 trial with a drug intervention (bimekizumab) and reports original results, but it is not an oncology trial (psoriatic arthritis) and does not include a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoints are patient-reported outcomes (EQ-5D-3L) and work productivity (WPAI-SHP), which are not time-to-event survival outcomes.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Statistical Concept for Conditional Marketing Authorisation Based on the Intermediate and Final Outcomes of a Single Confirmatory Randomised Clinical Trial. PMID 41701010 · Pharm Stat · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Sucralose as a Way to Enhance Regulatory T Cells, the SWEET Trial: Clinical Research Protocol. PMID 41694241 · Can J Kidney Health Dis · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Actigraphy-Quantified Physical Activity Measurements in Patients with Symptomatic LMNA-Related Dilated Cardiomyopathy in REALM-Dilated Cardiomyopathy. PMID 41693767 · Digit Biomark · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Acupuncture combined with immunotherapy for recurrent and metastatic cervical cancer: a pilot RCT protocol. PMID 41684588 · Front Oncol · 2026 The record is a protocol for a randomized trial in cervical cancer, which meets oncology, human, randomized, and drug intervention criteria. However, it does not present results; it is a protocol. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III (it is described as a 'pilot' and 'first' RCT, which does not establish definitive-phase evidence). The primary endpoint (ORR) is not a time-to-event endpoint, though PFS and OS are listed as secondary endpoints. Therefore, it is excluded as a protocol without results and due to unclear phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Study protocol for a multicenter phase II prospective externally controlled non-inferiority trial of hypofractionated re-irradiation in patients with recurrent high-grade glioma (RISinG). PMID 41662245 · PLoS One · 2026 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
KRAS p.G12C mutated-targeted treatments in metastatic colorectal cancer: a systematic review and meta-analysis. PMID 41612983 · Ann Gastroenterol · 2026 The record is a systematic review and meta-analysis of multiple early-phase trials, not an original report of a single Phase III/IIIb or Phase II/III randomized trial. The abstract does not report any time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or Kaplan-Meier/HR data.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomised pilot trial of perioperative propranolol combined with celecoxib versus standard of care in stage III melanoma: The ProCel study protocol. PMID 41610103 · PLoS One · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Patient-Reported Outcomes after Surgery for Proliferative Vitreoretinopathy: Post hoc Analysis of a Randomized Controlled Trial. PMID 41610080 · Ophthalmologica · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Digital health interventions for cervical cancer screening among hard-to-reach women in health-resource-limited areas: Protocol for a controlled trial with historical controls and two randomised intervention arms. PMID 41602939 · Digit Health · 2026 This is a protocol for a randomized controlled trial evaluating a digital health intervention (web/WeChat platform) for cervical cancer screening, not a drug intervention. It reports no efficacy results (Kaplan-Meier, HR, time-to-event endpoints) and is a Phase not specified as III/IIIb or II/III. Therefore, it does not meet the eligibility criteria for inclusion in the KM digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant Chemotherapy with Traditional Chinese Herbal Granules Versus Placebo in Resected Non-Small Cell Lung Cancer: Updated Survival Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. PMID 41589575 · Integr Cancer Ther · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Topical Tofacitinib for Atopic Dermatitis - Outcomes from Randomized Phase 3 Clinical Trial: First Approval. PMID 41585823 · Indian J Dermatol · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Olezarsen in Patients With Hypertriglyceridemia: A Meta-Analysis of Randomized Controlled Trials. PMID 41542285 · Cardiovasc Ther · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Determinants of publication likelihood and timeliness for clinical studies. PMID 41536814 · J Clin Transl Sci · 2026 The record is a meta-analytical study of factors predicting publication timeliness for clinical trials, not an original report of a Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary time-to-event endpoint. It lacks the specific trial results required.
S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial. PMID 41531249 · Helicobacter · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptions. PMID 41526135 · Handb Clin Neurol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease. PMID 41522368 · Alzheimers Dement (N Y) · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial. PMID 41519383 · Asia Pac J Ophthalmol (Phila) · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Randomized trial of dose de-escalation in low-risk prostate cancer patients implanted with Pd-103. PMID 41494910 · Brachytherapy · 2026 The study is a randomized trial with a primary time-to-event endpoint (biochemical failure) for human prostate cancer. However, it fails the drug intervention criterion because the intervention is brachytherapy (a radioisotope treatment), not a systemic drug therapy. The phase of the trial is not explicitly stated in the provided metadata as Phase III/IIIb or Phase II/III, but even if it were, the absence of a drug intervention makes it ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nicotinamide and Pyruvate in Open-Angle Glaucoma: A Randomized Controlled Trial on Neuroprotection-Design and Methodology. PMID 41461224 · Ophthalmol Glaucoma · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma. PMID 41453647 · Ann Hepatol · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Frontline Pembrolizumab or Methotrexate in Elderly, Frail, or Cisplatin-Ineligible Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of the Randomized Phase 2 Study ELDORANDO (AIO-KHT-0115). PMID 41428603 · Oncol Res Treat · 2026 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Study on the Improvement of Quality of Survival in Cervical Cancer Patients after Chemoradiotherapy through an Integrated Traditional Chinese and Western Medicine Therapy Based on a Syndrome Differentiation-Driven Dynamic Intervention Strategy. PMID 41343416 · Oncology · 2026 The study is a randomized oncology trial reporting primary OS results via Kaplan-Meier and Cox regression, but the intervention is a non-drug-only regimen (integrated Chinese and Western medicine therapy without specified drug-containing component), and the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
MG-K10, a Long-Acting Anti-IL-4 Receptor Alpha Monoclonal Antibody in Adult Patients with Moderate-to-Severe Atopic Dermatitis. PMID 41189512 · Dermatitis · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
[Translated article] Network meta-analysis of perioperative immunotherapies in non-small-cell lung cancer according to tumor programmed death ligand 1 expression. PMID 41188103 · Farm Hosp · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparative Efficacy of all Available Pharmaceutical Therapies for Moderate to Severe Crohn's Disease: A Systematic Review and Network Meta-Analysis. PMID 41140764 · Gastro Hep Adv · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of cardiac myosin inhibitors in obstructive hypertrophic cardiomyopathy: Systematic review and comprehensive frequentist and Bayesian meta-analyses of Phase 3 randomized controlled trials. PMID 41093262 · Prog Cardiovasc Dis · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Vitamin Profile of the Patients with Chronic Kidney Disease Receiving a Novel Total Parenteral Nutrition Formula: Multicenter Randomized Controlled Phase III Trial. PMID 40906605 · Ann Nutr Metab · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
ConquerFear-HK: A Randomized Controlled Trial of a Metacognition-Based, Manualized Intervention for Fear of Cancer Recurrence among Chinese Cancer Survivors. PMID 40784346 · Psychother Psychosom · 2026 The study is an oncology randomized controlled trial reporting original results, but it is ineligible because it lacks a drug intervention and its primary endpoint is not a time-to-event efficacy measure.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Volumetric Changes and Acute Toxicity With 68Ga Prostate-Specific Membrane Antigen Versus 18F-Fluciclovine Positron Emission Tomography/Computer Tomography Guided Postprostatectomy Radiation: Final Analysis of a Randomized Trial. PMID 40738247 · Pract Radiat Oncol · 2026 The report is a primary, randomized, human oncology trial, but it is excluded because it lacks a time-to-event efficacy endpoint and does not involve a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study. PMID 40652928 · Acta Haematol · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis. PMID 40152029 · Dermatitis · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -